EUVIMEDEUVIMED entdecken
Crossref

Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations

Lieke Mous iD, Stelly Ballet iD, Sylvain Dureau, Camille Benoist, Eleonore Frouin, Victor Renault iD, Laura Kirton iD, Peter Peneder iD, Nina Jehanno iD, Anja L Frei, Stéphanie Reynaud iD, Eve Lapouble iD und 26 weitere

Journal of Clinical Oncology · 04.11.2026

DOI: 10.1200/jco-26-00280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 04.11.2026. Verfasst von Lieke Mous und 37 weiteren Autor:innen. Beteiligte Einrichtung: Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Zurich, Switzerland. Die Arbeit nennt 54 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.

Autor:innen und Institutionen

  • Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Zurich, Switzerland.
  • Genetics Department Curie Institute & PSL Research University, Paris, France.
  • Department of Biometry, Curie Institute, Saint Cloud, France.
  • PSL Research University and Clinical Bioinformatics Unit, Curie Institute, Paris, France.
  • Cancer Research UK Clinical Trials Unit, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom.
  • St Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.

ORCID-Profile: Lieke Mous, Stelly Ballet, Victor Renault, Laura Kirton, Peter Peneder, Nina Jehanno, Stéphanie Reynaud, Eve Lapouble, Aurélie Guinot, Piers Gaunt, Sandra J Strauss, Manuela Krumbholz, Markus Metzler, Susan A Burchill, Martin G McCabe, Nathalie Gaspar, Birgit Geoerger, Gudrun Schleiermacher, Nadège Corradini, Bernadette Brennan, Perrine Marec-Berard, Gaelle Pierron, Didier Surdez

Zitieren

APA

Mous, L., Ballet, S., Dureau, S., Benoist, C., Frouin, E., Renault, V., Kirton, L., Peneder, P., Jehanno, N., Frei, A. L., Reynaud, S., Lapouble, E., Plissonnier, A. S., Legrier, M. E., Blanc, E., Guinot, A., Anderton, J., Gaunt, P., Evans, A., …, & Surdez, D. (2026). Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00280

Vancouver

Mous L, Ballet S, Dureau S, Benoist C, Frouin E, Renault V, et al. Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00280

BibTeX
@article{Mous2026,
  author = {Mous, Lieke and Ballet, Stelly and Dureau, Sylvain and Benoist, Camille and Frouin, Eleonore and Renault, Victor and Kirton, Laura and Peneder, Peter and Jehanno, Nina and Frei, Anja L and Reynaud, Stéphanie and Lapouble, Eve and Plissonnier, Anne-Sophie and Legrier, Marie-Emmanuelle and Blanc, Ellen and Guinot, Aurélie and Anderton, Jennifer and Gaunt, Piers and Evans, Abigail and Strauss, Sandra J and Krumbholz, Manuela and Metzler, Markus and Roundhill, Elizabeth A and Burchill, Susan A and Abbou, Samuel and Winter, Sarah and McCabe, Martin G and Gaspar, Nathalie and Geoerger, Birgit and Schleiermacher, Gudrun and Tomazou, Eleni M and Corradini, Nadège and Laurence, Valerie and Brennan, Bernadette and Marec-Berard, Perrine and Delattre, Olivier and Pierron, Gaelle and Surdez, Didier},
  title = {Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00280}
}
Kostenlos starten →